Literature DB >> 1409122

Presence of calcitonin-like immunoreactivity (iCT) in human prostate gland: evidence for iCT secretion by cultured prostate cells.

G V Shah1, M J Noble, M Austenfeld, J Weigel, L J Deftos, W K Mebust.   

Abstract

Immunoreactive calcitonin (iCT) has been detected in human prostate tissue extracts as well as seminal plasma. The present studies were undertaken to examine whether iSCT (immunoreactive salmon CT-like human peptide) co-exists with iHCT (thyroid CT-like substance) in human prostate tissue extracts, and whether these substances are secreted by primary prostate cells in culture. Since the local secretion of these substances seems to increase in some neoplasms, a second objective of the study was to examine whether basal secretion of iCTs from primary prostate cells is increased in carcinoma. The present results have shown that both iHCT and iSCT were present in prostate tissue extracts. The mean iHCT levels in extracts of benign hyperplastic prostates (BPH) were 0.59 ng/g prostate, and these were significantly lower than iHCT concentrations in prostatic carcinoma (PC) (2.53 ng/g). No significant differences in their iSCT contents were observed. However, the results from culture of over 90 individual prostate tissue specimens from BPH or PC indicate that primary prostate cells secreted detectable quantities of iSCT and the basal release of this material from PC prostate cultures was almost four-fold higher than that from BPH prostate cultures. These results suggest that a CT-like immunoreactive material is secreted by primary prostate cells in culture, and the basal secretion of this material is significantly higher in PC cells as compared to BPH cells. Endogenous secretion of prostatic CT, and the elevation of its expression in PC suggest that it may serve as a regulatory factor in the pathophysiology of the prostate gland.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1409122     DOI: 10.1002/pros.2990210202

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

Review 1.  Neuroendocrine peptides in the prostate.

Authors:  P J Gkonos; A Krongrad; B A Roos
Journal:  Urol Res       Date:  1995

2.  Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells.

Authors:  Khalid A El Sayed; Mohammad A Khanfar; Hassan M Shallal; A Muralidharan; Bhushan Awate; Diaa T A Youssef; Yang Liu; Yu-Dong Zhou; Dale G Nagle; Girish Shah
Journal:  J Nat Prod       Date:  2008-02-26       Impact factor: 4.050

Review 3.  Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate.

Authors:  M A Noordzij; G J van Steenbrugge; T H van der Kwast; F H Schröder
Journal:  Urol Res       Date:  1995

Review 4.  The Role of the Calcitonin Peptide Family in Prostate Cancer and Bone Metastasis.

Authors:  Jessica Isabel Warrington; Gareth Owain Richards; Ning Wang
Journal:  Curr Mol Biol Rep       Date:  2017-08-02

5.  Occurrence and reproductive roles of hormones in seminal plasma.

Authors:  Jana Vitku; Lucie Kolatorova; Richard Hampl
Journal:  Basic Clin Androl       Date:  2017-09-08

6.  MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells.

Authors:  Eric W Robbins; Emily A Travanty; Kui Yang; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2008-09-15       Impact factor: 4.430

Review 7.  Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

Authors:  Harm Westdorp; Annette E Sköld; Berit A Snijer; Sebastian Franik; Sasja F Mulder; Pierre P Major; Ronan Foley; Winald R Gerritsen; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2014-05-06       Impact factor: 7.561

8.  Calcitonin Receptor-Zonula Occludens-1 Interaction Is Critical for Calcitonin-Stimulated Prostate Cancer Metastasis.

Authors:  Ahmed Aljameeli; Arvind Thakkar; Shibu Thomas; Vijaybasker Lakshmikanthan; Kenneth A Iczkowski; Girish V Shah
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.